Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer’s Disease in Amnestic Mild Cognitive Impairment Subjects

G. M. Giuffrè,Davide Quaranta,M. G. Vita,E. M. Costantini,S. Citro,C. Carrozza,G. De Ninno,P. Calabresi,C. Marra,G.M. Giuffrè,D. Quaranta,M.G. Vita,E.M. Costantini

DOI: https://doi.org/10.14283/jpad.2024.58

2024-01-01

Abstract:IntroductionNovel plasma biomarkers are promising for identifying Alzheimer’s disease (AD) pathological processes in vivo, but most currently employed assays have limitations precluding widespread use.MethodsCSF and plasma samples were collected from seventy amnestic mild cognitive impairment (aMCI) subjects, stratified as A+ and A−. CSF Aβ40, Aβ42, p-tau181 and t-tau and plasma Aβ40, Aβ42 and p-tau181 quantification were conducted using the Lumipulse G assays (Fujirebio), to evaluate the diagnostic performance of plasma biomarkers and assess their associations with CSF biomarkers.ResultsAll plasma biomarkers except Aβ40 showed a very good accuracy in distinguishing A+ aMCI from A− aMCI, Aβ42/p-tau181 ratio being the most accurate (AUC 0.895, sensitivity 95.1%, specificity 82.8%). Plasma biomarkers levels were significantly associated with CSF biomarkers concentration.DiscussionHigh-throughput and fully-automated plasma assays could be helpful in discriminating with high accuracy between aMCI in the AD continuum and aMCI unlikely due to AD in clinical settings.

clinical neurology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the diagnostic performance of a new fully - automated high - throughput plasma biomarker detection method (Lumipulse G) in differentiating amnestic mild cognitive impairment (aMCI) patients in the Alzheimer's disease (AD) continuum from aMCI patients not caused by AD, and to evaluate the associations between these plasma biomarkers and cerebrospinal fluid (CSF) biomarkers.

Specifically, the researchers focused on three biomarkers in plasma, namely Aβ40, Aβ42 and p - tau181. By using the Lumipulse G detection system to measure the levels of these markers, they further evaluated their ability to identify whether the cognitive impairment in aMCI patients was caused by AD. In addition, the study also explored the relationships between these plasma biomarkers and known CSF biomarkers to verify the effectiveness and reliability of these plasma markers as early - diagnosis tools for AD.

The significance of this study lies in that it provides a possible alternative, which can reduce the dependence on invasive examinations (such as CSF detection) and expensive imaging examinations (such as PET scans), thereby providing a more convenient and cost - effective approach for the early diagnosis of AD. This is of great significance for increasing the early identification rate of AD patients and selecting appropriate patient groups for potential disease - modifying treatments.